HWHG(SH:600079) Zheng Quan Ri Bao·2025-10-13 14:09Core Viewpoint - The announcement indicates that the company has received regulatory approval for a new drug, which could enhance its product portfolio and market position in the pharmaceutical industry [2] Group 1: Company Developments - The company, Renfu Pharmaceutical, announced that its subsidiary, Wuhan Jiulong Renfu Pharmaceutical Co., Ltd., has received the Drug Registration Certificate for Dapoxetine Hydrochloride Tablets from the National Medical Products Administration [2] - The subsidiary is fully owned by another subsidiary, Hubei Gedian Renfu Pharmaceutical Co., Ltd., indicating a structured ownership within the company [2] Group 2: Industry Implications - The approval of Dapoxetine Hydrochloride Tablets may signify a competitive advantage in the pharmaceutical market, particularly in the treatment of premature ejaculation, which is a significant unmet medical need [2] - This development aligns with the ongoing trend in the pharmaceutical industry towards expanding therapeutic options and addressing specific health concerns [2]